Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes

Journal of Pathology

Volumn 232, Issue 1, 2014, Pages 32-42

  Lawrie, Charles H ^a,b,c   Larrea, Erika ^a   Larrinaga, Gorka ^d   Goicoechea, Ibai ^a   Arestin, María ^a   Fernandez Mercado, Marta ^a   Hes, Ondrej ^e   Cáceres, Francisco ^f   Manterola, Lorea ^a   Lõpez, José I ^d  

^a BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BASQUE FOUNDATION FOR SCIENCE   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e CHARLES UNIVERSITY   (Czech Republic)

^f HOSPITAL DE CRUCES   (Spain)

Author keywords

clear cell papillary renal cell carcinoma; EMT; miRNA; non coding RNA; renal carcinoma

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; MESSENGER RNA; MICRORNA; SMALL CAJAL BODY SPECIFIC RNA; SMALL NUCLEOLAR RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA; UVOMORULIN; VIMENTIN;

ARTICLE; CLEAR CELL CARCINOMA; CLEAR CELL TUBULOPAPILLARY RENAL CELL CARCINOMA; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MET PROTO ONCOGENE; MICROARRAY ANALYSIS; MIR 200 GENE; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTO ONCOGENE; RECURRENT CANCER; SOMATIC MUTATION; TARGETED NEXT GENERATION SEQUENCING;

CLEAR CELL PAPILLARY RENAL CELL CARCINOMA; EMT; MIRNA; NON-CODING RNA; RENAL CARCINOMA;

CARCINOMA, RENAL CELL; CLUSTER ANALYSIS; CZECH REPUBLIC; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RETROSPECTIVE STUDIES; RNA, NEOPLASM; RNA, UNTRANSLATED; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84890108527     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4296     Document Type: Article

References (85)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Souza DL, Bernal MM,. Incidence, prevalence and mortality of kidney cancer in Spain: estimates and projections for the 1998-2022 period. Actas Urol Esp 2012; 36: 521-526.
3. Nagashima Y, Inayama Y, Kato Y, et al., Pathological and molecular biological aspects of the renal epithelial neoplasms, up-to-date. Pathol Int 2004; 54: 377-386.
4. Lopez-Beltran A, Scarpelli M, Montironi R, et al., 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006; 49: 798-805.
5. Lopez JI,. Renal tumors with clear cells. A review. Pathol Res Pract 2013; 209: 137-146.
6. Tickoo SK, Reuter VE,. Differential diagnosis of renal tumors with papillary architecture. Adv Anat Pathol 2011; 18: 120-132.
7. Truong LD, Shen SS,. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med 2011; 135: 92-109.
8. Adam J, Couturier J, Molinie V, et al., Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases. Histopathology 2011; 58: 1064-1071.
9. Gobbo S, Eble JN, Grignon DJ, et al., Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol 2008; 32: 1239-1245.
10. Aydin H, Chen L, Cheng L, et al., Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol 2010; 34: 1608-1621.
11. Klatte T, Said JW, Seligson DB, et al., Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. J Urol 2011; 185: 30-35.
12. Rohan SM, Xiao Y, Liang Y, et al., Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol 2011; 24: 1207-1220.
13. Ross H, Martignoni G, Argani P,. Renal cell carcinoma with clear cell and papillary features. Arch Pathol Lab Med 2012; 136: 391-399.
14. Gilani SM, Tashjian R, Qu H,. Clear cell papillary renal cell carcinoma with characteristic morphology and immunohistochemical staining pattern. Pathologica 2012; 104: 101-104.
15. Williamson SR, Eble JN, Cheng L, et al., Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile. Mod Pathol 2013; 26: 697-708.
16. Mai KT, Faraji H, Desantis D, et al., Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study. Virchows Arch 2010; 456: 77-84.
17. Gobbo S, Eble JN, Maclennan GT, et al., Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis. Am J Surg Pathol 2008; 32: 1780-1786.
18. Al-Ali BM, Ress AL, Gerger A, et al., MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 2012; 32: 3727-3732.
19. Lawrie CH, Saunders NJ, Soneji S, et al., MicroRNA expression in lymphocyte development and malignancy. Leukemia 2008; 22: 1440-1446.
20. Gill S, Kandel S, B X. Frequency of clear cell papillary renal cell carcinoma in cases of low grade clear cell renal cell carcinoma. A 12 year retrospective study from a single cancer center (Abstract). Mod Pathol 2013; 26 (suppl 2): 212A.
21. Park JH, Lee C, Suh JH, et al., Clear cell papillary renal cell carcinoma: a report of 15 cases including three cases of concurrent other-type renal cell carcinomas. Korean J Pathol 2012; 46: 541-547.
22. Williamson SR, Zhang S, Eble JN, et al., Clear cell papillary renal cell carcinoma-like tumors in patients with von Hippel-Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma. Am J Surg Pathol 2013; 37: 1131-1139.
23. Korpal M, Kang Y,. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008; 5: 115-119.
24. Geurts-Giele WR, Dirkx-van der Velden AW, Bartalits NM, et al., Molecular diagnostics of a single multifocal non-small cell lung cancer case using targeted next generation sequencing. Virchows Arch 2013; 462: 249-254.
25. Yousem SA, Dacic S, Nikiforov YE, et al., Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest 2013; 143: 1679-1684.
26. Pagani F, Baralle FE,. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 2004; 5: 389-396.
27. Sauna ZE, Kimchi-Sarfaty C,. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 2011; 12: 683-691.
28. Tomei S, Adams S, Uccellini L, et al., Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population. Med Oncol 2012; 29: 3456-3461.
29. Wagner K, Damm F, Gohring G, et al., Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010; 28: 2356-2364.
30. Wang XW, Boisselier B, Rossetto M, et al., Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas. Cancer 2013; 119: 806-813.
31. Pugh TJ, Weeraratne SD, Archer TC, et al., Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488: 106-110.
32. Schraml P, Struckmann K, Hatz F, et al., VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002; 196: 186-193.
33. Brauch H, Weirich G, Brieger J, et al., VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000; 60: 1942-1948.
34. Wolfe A, Dobin SM, Grossmann P, et al., Clonal trisomies 7,10 and 12, normal 3p and absence of VHL gene mutation in a clear cell tubulopapillary carcinoma of the kidney. Virchows Arch 2011; 459: 457-463.
35. Kuroda N, Shiotsu T, Kawada C, et al., Clear cell papillary renal cell carcinoma and clear cell renal cell carcinoma arising in acquired cystic disease of the kidney: an immunohistochemical and genetic study. Ann Diagn Pathol 2011; 15: 282-285.
36. Schmidt L, Duh FM, Chen F, et al., Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73.
37. Seiwert TY, Jagadeeswaran R, Faoro L, et al., The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009; 69: 3021-3031.
38. Liu Y, Zhang Q, Ren C, et al., A germline variant N375S in MET and gastric cancer susceptibility in a Chinese population. J Biomed Res 2012; 26: 315-318.
39. Nakamura T, Kanda S, Yamamoto K, et al., Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation. Oncogene 2001; 20: 7610-7623.
40. Neklason DW, Done MW, Sargent NR, et al., Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer 2011; 11: 424.
41. Sattler M, Reddy MM, Hasina R, et al., The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 2011; 3: 171-184.
42. Loriaux MM, Levine RL, Tyner JW, et al., High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 2008; 111: 4788-4796.
43. Lee JH, Han SU, Cho H, et al., A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000; 19: 4947-4953.
44. Schmidt L, Junker K, Nakaigawa N, et al., Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18: 2343-2350.
45. Tyner JW, Fletcher LB, Wang EQ, et al., MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res 2010; 70: 6233-6237.
46. Gottardo F, Liu CG, Ferracin M, et al., Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007; 25: 387-392.
47. Nakada C, Matsuura K, Tsukamoto Y, et al., Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 2008; 216: 418-427.
48. Chow TF, Mankaruos M, Scorilas A, et al., The miR-17-92 cluster is over-expressed in and has an oncogenic effect on renal cell carcinoma. J Urol 2010; 183: 743-751.
49. Petillo D, Kort EJ, Anema J, et al., MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 2009; 35: 109-114.
50. Slaby O, Jancovicova J, Lakomy R, et al., Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 2010; 29: 90.
51. Huang Y, Dai Y, Yang J, et al., Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol 2009; 35: 1119-1123.
52. Juan D, Alexe G, Antes T, et al., Identification of a microRNA panel for clear-cell kidney cancer. Urology 2010; 75: 835-841.
53. Weng L, Wu X, Gao H, et al., MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol 2010; 222: 41-51.
54. Wu X, Weng L, Li X, et al., Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 2012; 7: e35661.
55. O'Hara AJ, Chugh P, Wang L, et al., Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma. PLoS Pathog 2009; 5: e1000389.
56. O'Hara AJ, Vahrson W, Dittmer DP,. Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood 2008; 111: 2347-2353.
57. Williams GT, Farzaneh F,. Are snoRNAs and snoRNA host genes new players in cancer? Nat Rev Cancer 2012; 12: 84-88.
58. Su H, Xu T, Ganapathy S, et al. Elevated snoRNA biogenesis is essential in breast cancer. Oncogene 2013.
59. Valleron W, Laprevotte E, Gautier EF, et al., Specific small nucleolar RNA expression profiles in acute leukemia. Leukemia 2012; 26: 2052-2060.
60. Ronchetti D, Todoerti K, Tuana G, et al., The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer J 2012; 2: e96.
61. Corless CL, Aburatani H, Fletcher JA, et al., Papillary renal cell carcinoma: quantitation of chromosomes 7 and 17 by FISH, analysis of chromosome 3p for LOH, and DNA ploidy. Diagn Mol Pathol 1996; 5: 53-64.
62. Neal CS, Michael MZ, Rawlings LH, et al., The VHL-dependent regulation of microRNAs in renal cancer. BMC Med 2010; 8: 64.
63. White NM, Bao TT, Grigull J, et al., miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 2011; 186: 1077-1083.
64. Li S, Chen T, Zhong Z, et al., microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Mol Med Rep 2012; 5: 949-954.
65. McCormick R, Buffa FM, Ragoussis J, et al., The role of hypoxia regulated microRNAs in cancer. Curr Top Microbiol Immunol 2010; 345: 47-70.
66. Chow TF, Youssef YM, Lianidou E, et al., Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 2010; 43: 150-158.
67. Nakada C, Tsukamoto Y, Matsuura K, et al., Overexpression of miR-210, a downstream target of HIF1α, causes centrosome amplification in renal carcinoma cells. J Pathol 2011; 224: 280-288.
68. Larkin J, Goh XY, Vetter M, et al., Epigenetic regulation in RCC: opportunities for therapeutic intervention? Nat Rev Urol 2012; 9: 147-155.
69. Liu H, Brannon AR, Reddy AR, et al., Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst Biol 2010; 4: 51.
70. Yamamura S, Saini S, Majid S, et al., MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. Carcinogenesis 2012; 33: 294-300.
71. Segura MF, Hanniford D, Menendez S, et al., Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 2009; 106: 1814-1819.
72. Jiang L, Mao P, Song L, et al., miR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol 2010; 177: 29-38.
73. Cekaite L, Rantala JK, Bruun J, et al., MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 2012; 14: 868-879.
74. Duns G, van den Berg A, van Dijk MC, et al., The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney. Genes Chromosomes Cancer 2013; 52: 165-173.
75. Davalos V, Moutinho C, Villanueva A, et al., Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2012; 31: 2062-2074.
76. Ding W, Dang H, You H, et al., miR-200b restoration and DNA methyltransferase inhibitor block lung metastasis of mesenchymal-phenotype hepatocellular carcinoma. Oncogenesis 2012; 1: e15.
77. Xiong M, Jiang L, Zhou Y, et al., The miR-200 family regulates TGFβ1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol 2012; 302: F369-379.
78. Korpal M, Lee ES, Hu G, et al., The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914.
79. Park SM, Gaur AB, Lengyel E, et al., The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
80. Ronkainen H, Kauppila S, Hirvikoski P, et al., Evaluation of myosin VI, E-cadherin and β-catenin immunostaining in renal cell carcinoma. J Exp Clin Cancer Res 2010; 29: 2.
81. Shen SS, Truong LD, Scarpelli M, et al., Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful? Arch Pathol Lab Med 2012; 136: 410-417.
82. Hurteau GJ, Carlson JA, Spivack SD, et al., Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007; 67: 7972-7976.
83. Wang Z, Li Y, Kong D, et al., The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets 2010; 11: 745-751.
84. Birchmeier C, Birchmeier W, Gherardi E, et al., Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925.
85. Lamorte L, Royal I, Naujokas M, et al., Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Mol Biol Cell 2002; 13: 1449-1461.